Detalhe da pesquisa
1.
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer.
Biomarkers
; 26(4): 302-308, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33645339
2.
Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2.
Lab Invest
; 100(1): 120-134, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31641225
3.
A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.
Gastric Cancer
; 23(5): 811-823, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32215766
4.
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
Ann Intern Med
; 168(5): 326-334, 2018 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29335712
5.
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
Mol Cancer
; 16(1): 116, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28683746
6.
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
BMC Cancer
; 17(1): 97, 2017 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28158999
7.
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
Tumour Biol
; 37(8): 10697-702, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26867771
8.
Evolutionary mode and timing of dissemination of high-grade serous carcinomas.
JCI Insight
; 9(3)2024 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175731
9.
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
BMC Cancer
; 12: 454, 2012 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23039163
10.
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.
Mol Oncol
; 16(12): 2312-2329, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34890102
11.
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
Sci Rep
; 11(1): 23463, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34873230
12.
Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases.
Mol Oncol
; 15(4): 830-845, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33325154
13.
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.
ESMO Open
; 5(6): e001040, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33219056
14.
Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation- status.
Hum Mutat
; 29(11): E252-62, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18781614
15.
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
PLoS One
; 12(7): e0182030, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28759630
16.
Psychological distress related to BRCA testing in ovarian cancer patients.
Fam Cancer
; 14(4): 495-504, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25980896
17.
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
PLoS One
; 7(4): e36263, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22558411
18.
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Cancer Cell
; 19(2): 273-82, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21316605
19.
Germline PTEN mutations are rare and highly penetrant.
Hered Cancer Clin Pract
; 4(4): 177-85, 2006 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20223021
20.
t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations.
Br J Haematol
; 130(6): 845-51, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16156854